# OnCo record revolution-medicines (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/revolution-medicines/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "revolution-medicines" ;
  schema:name "Revolution Medicines"@en ;
  schema:alternateName "EQRx International, Inc."@en, "EQRx"@en ;
  schema:description "Revolution Medicines is the leading RAS company; its pan-RAS pill daraxonrasib (Rasonque) was approved in the US in August 2026 for previously treated metastatic pancreatic cancer."@en ;
  schema:url <https://onco.cc/companies/revolution-medicines/>, <https://www.revmed.com> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.revmed.com>, <https://www.sec.gov/Archives/edgar/data/1628171/000119312526366931/rvmd-20260826.htm> ;
  schema:addressCountry "US" ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:drugs <https://onco.cc/drugs/daraxonrasib/> ;
  onco:trials <https://onco.cc/trials/nct07491445/>, <https://onco.cc/trials/nct07805954/>, <https://onco.cc/trials/nct07252232/>, <https://onco.cc/trials/nct07621718/>, <https://onco.cc/trials/nct06881784/>, <https://onco.cc/trials/nct07777822/>, <https://onco.cc/trials/nct06445062/>, <https://onco.cc/trials/nct07397338/>, <https://onco.cc/trials/nct05379985/>, <https://onco.cc/trials/nct06162221/>, <https://onco.cc/trials/nct06128551/> .